“Global Diagnostic Imaging market set to grow to $32bn by 2024” says Visiongain report

20 September 2019
Pharma

Visiongain has launched a new pharma report Global Diagnostic Imaging Market Forecast 2019-2029: MRI Systems, Ultrasound Imaging Systems, CT Scanners, Nuclear Imaging, X-Ray Imaging, Mammography, Cardiology, Gynecology/Obs, Orthopaedics & Musculoskeletal, Radiology, Neurology & Spine, General Imaging, Hospitals, Diagnostic Imaging Centers.

Diagnostic imaging is an integral part of treatment decisions and also plays a role in therapy planning, therapy monitoring and follow-up.

The lead analyst of the report commented "Diagnostic imaging technology such as MRI and CT scans has become more precise and accessible, due to which radiology has increasingly become a key foundation of modern medicine. Currently, many of the diagnostic imaging devices are powered by artificial intelligence and machine learning. This would significantly improve diagnostic quality, efficiency, and treatment patterns.

The high cost associated with the clinical trials and development of diagnostic imaging devices coupled with the inefficient infrastructure is likely to impede the growth of the diagnostic imaging market."

Leading companies featured in the report include Canon, Inc., Carestream Health, Inc., Esaote SPA, FUJIFILM Holdings Corporation, GE Healthcare, Hitachi, Ltd., Koninklijke Philips N.V. (Royal Philips), Samsung Electronics Co., Ltd., Shimadzu Corporation, Siemens Healthineers AG and other companies.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Global Human Microbiome Therapeutics market set to grow to $1.6bn” by 2025 says new Visiongain report

The market for microbiome therapeutics is expected to commence around mid-2020 with the launch of new products relating to dermatology and gastrointestinal disorders.

04 December 2019

Read

“Global Next-Generation Biologics market set to grow to $42bn by 2024” says new Visiongain report

Technological developments in the next-generation biologics market will be the result of clinical development of multiple platforms in the next-generation antibody, antibody fragment and ALP sectors.

04 December 2019

Read

“Global Liquid Biopsy market set to grow to $4.9bn by 2024” says new Visiongain report

The main drivers for the growth include technological advancements such as development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.

04 December 2019

Read

“Global nucleic acid isolation and purification market is anticipated to reach USD 8.16 Billion by 2030”, says Visiongain

Nucleic acid separation and purification is one of modern science and technology’s most complex and critical accomplishments.

29 November 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever